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Abstract
The accuracy of Follicle Stimulating Hormone as a predictor of azoospermia in adult survi-
vors of childhood cancer is unclear, with conflicting results in the published literature. A sys-
tematic review and post hoc analysis of combined data (n = 367) were performed on all
published studies containing extractable data on both serum Follicle Stimulating Hormone
concentration and semen concentration in survivors of childhood cancer. PubMed and Med-
line databases were searched up to March 2017 by two blind investigators. Articles were
included if they contained both serum FSH concentration and semen concentration, used
World Health Organisation certified methods for semen analysis, and the study participants
were all childhood cancer survivors. There was no evidence for either publication bias or
heterogeneity for the five studies. For the combined data (n = 367) the optimal Follicle Stim-
ulating Hormone threshold was 10.4 IU/L with specificity 81% (95% CI 76%–86%) and
sensitivity 83% (95% CI 76%–89%). The AUC was 0.89 (95%CI 0.86–0.93). A range of
threshold FSH values for the diagnosis of azoospermia with their associated sensitivities
and specificities were calculated. This study provides strong supporting evidence for the
use of serum Follicle Stimulating Hormone as a surrogate biomarker for azoospermia in
adult males who have been treated for childhood cancer.
Introduction
The potential impact of childhood cancer treatment on male fertility is a significant issue for
both families at the time of diagnosis, and the young adult survivor [1, 2]. Treatment at any
age, with chemotherapy agents, particularly high doses of alkylating agents, and pelvic radio-
therapy, may damage the testes resulting in impaired sperm production[2–7]. While semen
analysis remains the gold standard, a serum biomarker of sufficient accuracy, for example
Follicle Stimulating Hormone (FSH) would provide a useful indirect assessment of fertility.
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The feedback relationship between the seminiferous tubule and the hypothalamus/pituitary
underpins the putative value of FSH and inhibin B in the quantitative assessment of spermato-
genesis [8]. FSH concentrations are negatively related to sperm concentration in both normal
men and in those with testicular dysfunction, whereas serum inhibin B is positively related [9–
11]. Both can be used to aid discrimination of obstructive vs non-obstructive azoospermia in
infertile men [12] without clear benefit of one over the other, likely reflecting their interdepen-
dence and relationship to maturational stages of spermatogenesis [13].
The ready availability and acceptability of serum FSH analysis compared to semen analysis
makes it of potential value as a predictor of azoospermia in childhood cancer survivors (CCS),
but the literature contains conflicting reports of the sensitivity and specificity of plasma con-
centrations of FSH in this context. Green et al. [14] found that FSH was unsuitable as predictor
of azoospermia in CCS whilst Romerius et al. [15] concluded that FSH was an excellent predic-
tor. It is possible that sources of heterogeneity such as diagnosis, treatment regimens or puber-
tal status may account for this difference. It is also possible that there is little or no inherent
heterogeneity, in which case data can be combined from multiple studies in order to provide a
dataset suitable for improved assessment of the true level of diagnostic strength.
In this study we identified studies that have reported FSH and sperm concentrations in
CCS, and used them to (a) test the data for homogeneity and (b) to assess the value of FSH as a
diagnostic predictor of azoospermia in CCS.
Materials and methods
Using an established methodology [16–18], a scoping search was carried out using relevant
MeSH headings which generated 680 results on PubMed and 973 on Scopus. The Medline
search strategy used was 1. ’Follicle Stimulating Hormone/b 2. FSH.ti,ab. 3. Inhibin/bl 4.
Inhibin / 5. Follicle stimulating hormone.ti,ab. 6. exp Sperm Count/ 7. spermato$.ti,ab. 8.
semen/ 9. (male adj3 fertil$).ti,ab. 10. azoospermia.ti,ab. 11. semen analysis.ti,ab. 12. sperm
concentration.ti, ab. 13. oligospermia.ti,ab. 14. semen.ti,ab. 15. 1 or 2 or 3 or 4 or 5 16. 6 or 7
or 8 or 9 or 10 or 11 or 12 or 13 orm14 17. 15 and 16 18. (HUMANS not ANIMALS).sh. 19. 17
and 18. Only publications in written in English were screened.
The abstracts of all studies identified were screened, and any studies in cancer survivors
that had data on semen analysis and FSH levels were read in full. Studies were selected if they
met the following criteria: (i) they contained both serum FSH concentration and semen con-
centration (either as explicit values or reported in a scatterplot), (ii) World Health Organisa-
tion (WHO) certified methods [19] were used in the semen analysis; (ii) the study participants
were all childhood cancer survivors, or data was clearly demarcated between childhood cancer
survivors and normal controls, in which case only cancer survivor data was extracted; (iii) all
study designs were included except case reports. Searches were performed by TWK, LM and
WHBW using the PRISMA guidelines for reporting in systematic reviews and meta-analyses
[20] between June 2015 and March 2017 (S1 PRISMA checklist). Data extraction was per-
formed by TWK, LM and AIU using version 3.02 of WebPlotDigitizer (http://arohatgi.info/
WebPlotDigitizer)); intra- and inter-observer errors were less than 1% for all values, and the
extracted datasets closely match the originals in terms of descriptive statistics. Analysis of
study quality was performed by LM, RTM and WHBW using the Scottish Intercollegiate
Guidelines Network (SIGN) methodology (http://www.sign.ac.uk/assets/sign104_ev_levels.
pdf)); all included studies were assessed as 2+ or higher.
In addition to data identified from a systematic search of the literature, we included our
own data (S1 Table) used (but not explicitly reported or given as a scatterplot) in a CCS semen
quality study [21]. This study involved 33 male survivors of childhood cancer recruited from
Follicle Stimulating Hormone is an accurate predictor of azoospermia in childhood cancer survivors
PLOS ONE | https://doi.org/10.1371/journal.pone.0181377 July 20, 2017 2 / 11
The funders had no role in study design, data
collection and analysis, decision to publish, or
preparation of the manuscript.
Competing interests: The authors have declared
that no competing interests exist.
the oncology database at the Royal Hospital for Sick Children, Edinburgh, from whom FSH
levels were obtained in addition to semen concentrations determined according to WHO pro-
tocols. For each study participant, we recruited two age-matched controls (n = 66). The volun-
teers were recruited by means of advertisement in local media and through hospital out-
patient clinics, and selected on the basis of the absence of any clinical evidence, on history or
physical examination,of reproductive health problems. The Lothian Paediatric and Reproduc-
tive Medicine research ethics subcommittee approved the study, and all patients provided
written informed consent.
While recognising that different FSH assays were used in the studies included, a detailed
comparison has shown ‘fair to strong consistency’ between the relevant assays [22] with most
of the variability at the lower end of the normal range thus we have used extracted data without
further conversion.
Approval was not required from an ethics committee or institutional review board since
our research was limited to use of previously collected, non-identifiable data that has been
published in peer reviewed journals which is specifically excluded from Research Ethics Com-
mittee review by the National Research Ethics Service guidelines of the UK Health Research
Agency [23].
The risk of publication bias was visually assessed by constructing funnels plots, in which
calculated diagnostic accuracy is set against statistical precision [24]. In addition, we per-
formed a linear regression of log diagnostic ratios on the inverse root of effective sample sizes
as a test for funnel plot asymmetry, where a non-zero slope coefficient is suggestive of signifi-
cant asymmetry and small study bias [25].
Initial analysis considered the heterogeneity or otherwise of the included studies. This was
tested using four distinct techniques: visually by forest plots [26], numerically by calculating
the slope of the affine regression equation linking the study diagnostic odds ratios (DOR) to
the study thresholds [27, 28] (where a slope close to zero shows homogeneity of the studies),
and statistically by (i) calculating the p-value for the chi-squared test of the hypothesis that the
studies are heterogeneous (a high p-value suggests homogeneity) and (ii) calculating Higgins
I2 statistic for measuring inconsistency in meta-analyses [29] (a small value suggests homoge-
neity). Two statistical tests were used as the interpretation of I2 can be misleading, since the
importance of inconsistency depends on several factors and the magnitude and direction of
effects could lead to a small I2 despite a large chi-squared p-value [30].
After combining the data into a single set of (FSH, azoospermic or not azoospermic) pairs,
a ROC curve was constructed. 95% confidence intervals for the AUC were calculated using
200 bootstraps of the data set, as were the optimal threshold (i.e. the level of FSH that maxi-
mizes the probability of a randomly-selected (azoospermic, not azoospermic) pair from the
CCS population being correctly diagnosed) and the 95% confidence intervals for the specificity
and sensitivity at each threshold value. All analyses were performed using the mada and pROC
packages for the R statistical language [31].
Results
The application of inclusion and exclusion criteria to the studies found in the literature yielded
four sources of FSH and semen concentration in CCS (Table 1, S2 Table, Fig 1) [5, 14, 32, 33].
Studies identified for full-text analysis, but excluded are listed in S1 References together with
reasons for exclusion. The Chi-squared statistical test for funnel plot asymmetry (Fig 2) did
not reach statistical significance (p = 0.32 for sensitivity; p = 0.17 for specificity), suggesting
that neither studies with small sample size nor studies with results lacking statistical signifi-
cance are missing from the literature. As all the included studies used WHO protocols, we
Follicle Stimulating Hormone is an accurate predictor of azoospermia in childhood cancer survivors
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conclude that they are at low risk of bias and have low concern about applicability, as specified
by the QUODAS-2 and STARD frameworks for reporting diagnostic accuracy [34, 35].
The confidence intervals for the log-adjusted DOR for each study have similar ranges, sug-
gesting a lack of significant study heterogeneity (Fig 3). Visual inspection shows that each
study is statistically significant in its own right, that the intervals overlap to a great extent, and
that therefore the studies are unlikely to be heterogeneous. The slope of the regression equa-
tion linking the study log DOR to the study FSH thresholds was close to zero (slope = -0.01),
providing numerical evidence for study homogeneity. The chi-squared p-values were 0.32 for
study sensitivity and 0.17 for study specificity, supplying no statistically significant evidence
for the hypothesis that the studies are heterogeneous. The Higgin’s I2 statistic was 0%, the low-
est possible indication of study heterogeneity. Taken together, and in conjunction with the
lack of publication bias, we conclude that the studies are homogeneous in terms of dependency
on FSH thresholds to determine diagnostic accuracy, and hence that combining the study data
into a single set results in a representative sample of the CCS population in terms of FSH levels
and sperm concentrations.
Table 1. Characteristics of the included studies.
1st Author Year PubMed ID Number CSS Age
(years, median
& range)
Green 2013 23423746 257 30.5, 19.7–59.1
La¨hteenma¨ki 2008 18430073 23 20.5, 15.6–31.2
Rendtorff 2012 21726269 37 25, 19–45
van Beek 2007 17981817 17 27, 17.7–42.6
Thomson 2002 12241775 33 21.9, 16.5–35.2
https://doi.org/10.1371/journal.pone.0181377.t001
Fig 1. Flow-chart of systematic search methodology. n = number of studies; N = number of childhood cancer
survivors fulfilling criteria.
https://doi.org/10.1371/journal.pone.0181377.g001
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For the combined data (n = 367, SI 1, SI 2) the optimal FSH threshold was 10.4 IU/L with
specificity 81% (95% CI 76%–86%) and sensitivity 82% (95% CI 76%–88%). The AUC was
0.89 (95%CI 0.85–0.92), demonstrating that FSH is a strong predictor of azoospermia for CCS
(Fig 4).
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Fig 2. Funnel plots for specificity (upper panel) and sensitivity (lower panel) relating study size to
reported diagnostic accuracy for the five studies listed in Table 1. The Chi-squared statistical test for
funnel plot asymmetry did not reach statistical significance (p = 0.32 for sensitivity; p = 0.17 for specificity),
suggesting a lack of publication bias.
https://doi.org/10.1371/journal.pone.0181377.g002
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The optimal threshold maximizes the chance of a correct classification for an arbitrary sur-
vivor of childhood cancer. In order to quantify FSH levels that minimize misdiagnosis of azoo-
spermia, a range of threshold FSH values for the diagnosis of azoospermia were calculated,
van Beek et al.
Green et al.
Lahteenmaki et al.
Rendtorrf et al.
Thomson et al.
3.93 [0.74, 7.12]
3.08 [2.43, 3.74]
4.14 [0.93, 7.35]
2.53 [0.89, 4.17]
5.20 [2.07, 8.32]
log diagnostic odds ratio
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Fig 3. Forest plot of 95% confidence limits for the log-adjusted diagnostic odds ratio for the five
studies listed in Table 1. The vertical dashed line denotes the line of no effect. Visual inspection shows that
each study is statistically significant in its own right, that the intervals overlap to a great extent, and that
therefore the studies are unlikely to be heterogeneous.
https://doi.org/10.1371/journal.pone.0181377.g003
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Fig 4. Receiver-operator characteristic (ROC) curve analysis of FSH as predictor of azoospermia
(combined cohort: n = 367). Area under the curve: 089 (95% CI 085–092. The optimal diagnostic
threshold is 10.4 mIU/mL, with sensitivity 0.814 and specificity 0.823.
https://doi.org/10.1371/journal.pone.0181377.g004
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together with the median and 95% confidence intervals for their associated sensitivities and
specificities (Table 2). A diagnostic threshold of 17 IU/L for FSH gives 94% probability of
avoiding misdiagnosis of azoospermia, with 95% confidence interval 90–97% (Table 2).
Discussion
We have shown that FSH has strong diagnostic power, with 89% probability that FSH levels
will correctly classify as azoospermic, not azoospermic a randomly chosen survivor of child-
hood cancer (i.e. positive predictive value) [36], with 95% confidence that this probability is
within 85% and 92% (Fig 4). For the combined data (n = 367) the optimal Follicle Stimulating
Hormone threshold was 10.4 IU/L with specificity 81% (95% CI 76%–86%) and sensitivity
83% (95% CI 76%–89%). The AUC was 0.89 (95%CI 0.86–0.93). This study provides strong
supporting evidence for the use of serum Follicle Stimulating Hormone as a surrogate bio-
marker for azoospermia in adult males who have been treated for childhood cancer. We have
also calculated clinically-useful diagnostic levels for a range of FSH thresholds (Table 2).
We have assessed heterogeneity of existing studies using visual, numeric modelling and two
distinct statistical tests; none of these suggested any important level of heterogeneity (Figs 2
and 3). This result is of clinical and biomedical interest in its own right, but also allows us
safely to combine the data into a single set, which has greater power for statistical analysis than
any single study reported to date. While different FSH assays were used in the studies included
in this analysis, there is good concordance between them [22].
FSH, inhibin B, and more recently anti-Mullerian hormone have been previously investi-
gated as biomarkers of seminiferous tubule function, often to attempt to predict the surgical
recovery of sperm in azoospermic men [12]. The latter two are products of the Sertoli cell,
with potentially an additional contribution to serum inhibin B from germ cells [37]. In the
post-chemotherapy testis, the key pathology determining azoospermia or not is the presence
or absence of spermatogonial stem cells at the end of treatment. This differs therefore from the
situation in the more general male infertility population, where disorders of spermatogenic
maturation are relatively common, with likely impact on the germ cell-Sertoli cell interaction
and production of inhibin B, and feedback regulation of FSH. It is thus possible that serum
biomarkers of spermatogenesis may be more accurate in post-chemotherapy assessment than
Table 2. Sensitivity and specificity of FSH-based azoospermia diagnosis for a range of threshold values. Median and 95% CI are calculated from
2,000 stratified bootstrap replicates of the combined data (n = 367).
Threshold FSH (IU/L) Specificity
Median
Specificity
95% CI
Sensitivity
Median
Sensitivity
95% CI
9 0.743 0.690–0.801 0.851 0.787–0.901
10 0.783 0.730–0.836 0.830 0.766–0.894
10.4 0.814 0.761–0.863 0.823 0.759–0.897
11 0.827 0.774–0.872 0.801 0.731–0.865
12 0.858 0.810–0.903 0.773 0.702–0.837
13 0.885 0.845–0.925 0.752 0.681–0.823
14 0.898 0.858–0.938 0.716 0.638–0.780
15 0.916 0.881–0.951 0.695 0.617–0.766
16 0.925 0.889–0.956 0.660 0.582–0.731
17 0.938 0.903–0.969 0.638 0.560–0.723
18 0.947 0.916–0.974 0.610 0.532–0.688
19 0.951 0.920–0.978 0.589 0.511–0.674
20 0.969 0.943–0.991 0.553 0.468–0.638
https://doi.org/10.1371/journal.pone.0181377.t002
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with the wide range of pathologies seen in the general infertile population. We considered the
potential value of including these biomarkers in a joint model, but there were insufficient data
to do this at present.
Our calculated optimal FSH threshold for classifying a CCS as azoospermic is 10.4 UI/L,
where optimal means providing the best tradeoff between sensitivity (i.e. minimized predic-
tion of non-zero sperm concentration for CCS who are in reality azoospermic) and specificity
(i.e. minimized prediction of azoospermia for CCS who in reality have non-zero sperm con-
centration). In clinical practice of long-term follow up of CCS, however, we suggest that a
more conservative threshold is more appropriate, since a wrong diagnosis of azoospermia is
worse than a false negative. It should also be emphasized that in some azoospermic CCS it is
possible to obtain sperm by micro-TESE [38]. The bootstrap sampling used to provide the
optimal threshold (necessarily) allows calculation of confidence intervals for sensitivities and
specificities for all potential thresholds, and from these we observe that a diagnostic threshold
of 17 IU/L for FSH has a 94% probability of avoiding this misdiagnosis, with 95% confidence
interval of 90%–97% (Table 2). Our specificity results are in quantitative agreement with a
study that reported mean FSH of 22 IU/L in 21 azoospermic CSS compared to 9 IU/L in 10
controls with 81% specificity at a 10 IU/L cutoff [39] compared to our value of 78%. However
our calculated sensitivity at this cutoff is higher: 56% [39] compared to 83%.
Serum assessment of FSH is therefore a useful test before the patient is ready to submit a
semen sample for analysis, and the present analysis indicates high predictive accuracy.
Attempts to survey CCS with universal semen analysis have demonstrated the reluctance of
these patients to submit semen samples. In contrast, a blood test is less intrusive and more
acceptable to these young CCS [32]. The use of hormone measurement in dried blood spots
sent by post has recently been evaluated in the analysis of reproductive function in female can-
cer survivors [40], and this technique has clear potential to be useful in the male case.
This study provides strong supporting evidence for the use of serum FSH as a useful surro-
gate biomarker for spermatogenesis in adult males who have been treated for childhood can-
cer, however semen analysis should always be encouraged and remains the gold standard test
of spermatogenesis.
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